Certain MRI Findings May Predict Future Cardiac Events
Cardiac magnetic resonance imaging may help clinicians predict future cardiac events among patients with coronary artery disease or recent MI.
Some MR imaging findings, such as left ventricular ejection fraction (LVEF), may have prognostic value regarding future cardiac events, according to a study published in the Journal of the American College of Cardiology.
Researchers from the Netherlands undertook a meta-analysis to review the prognostic value of cardiac magnetic resonance (CMR) in for future cardiovascular events in patients with coronary artery disease (CAD) or a recent myocardial infarction (MI).
The researchers identified 56 studies with 25,497 patients. After review, the researchers found that too few patients with a recent MI had been evaluated to establish associations between CMR findings and hard events (all-cause mortality, cardiac death, cardiac transplantation, and MI). However, it was found that in this group, LVEF was independently associated with major adverse cardiac events (MACE).
For patients with suspected or known CAD, the studies showed that wall motion abnormalities, inducible perfusion defects, LVEF, and infarction were independently associated with hard events. As well, the presence of inducible perfusion defects was associated with MACE.
The authors concluded that these findings indicate the utility of developing reporting guidelines using CMR among patients with CAD or recent MI.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
